Arrowhead Pharmaceuticals Inc (ARWR) Stock Analysis
Verdict: WATCH (do not buy)
Redemplo's slow-burn commercial guidance and heavy clinical cash burn trigger a sell-the-news correction despite robust RNAi platform execution.
Investment score: 46/100
Analysis as of
Is Arrowhead Pharmaceuticals Inc stock worth reviewing? AI model thesis
The AI model views ARWR as a HOLD. While Arrowhead's RNAi pipeline (Redemplo, ARO-DIMER-PA) shows high clinical potential, management's warning of a slow-burn commercial roll-out ($3B-$4B peak) alongside severe insider selling (33 sales, 0 buys) and a 20.4% 5-day drop creates high short-term execution uncertainty.
7-factor investment score
- Valuation: 40/100 (weight 20%)
- Financial Health: 50/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 50/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 55/100 (weight 15%)
Arrowhead Pharmaceuticals Inc opportunities and risks
What speaks for ARWR
- Commercial expansion of Redemplo in familial chylomicronemia syndrome provides long-term market potential.
What speaks against ARWR
- High cash burn in non-partnered clinical trial years creates recurring balance sheet dilution risk.
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| ARWR | n/a | 13.8x | n/a | 100.0% | -47.8% | -0.8% |
| KRYS | 40.7x | 22.5x | 43.5x | 93.3% | 54.8% | 2.6% |
| KYMR | n/a | 91.1x | n/a | 102.0% | -285.4% | -2.5% |
| CYTK | n/a | 121.7x | n/a | 85.0% | -1259.9% | -6.7% |
| TWST | n/a | 20.6x | n/a | 52.0% | -31.7% | -1.0% |
| PTGX | 117.3x | 32.6x | 102.7x | 99.9% | 29.4% | 1.4% |
| Peer median | n/a | 32.6x | n/a | 93.3% | -31.7% | -1.0% |
Frequently asked questions about Arrowhead Pharmaceuticals Inc (ARWR)
Is ARWR stock a good investment?
The cached TradeMates AI model rates Arrowhead Pharmaceuticals Inc as WATCH (do not buy) with an investment score of 46/100. The AI model views ARWR as a HOLD. While Arrowhead's RNAi pipeline (Redemplo, ARO-DIMER-PA) shows high clinical potential, management's warning of a slow-burn commercial roll-out ($3B-$4B peak) alongside severe insider selling (33 sales, 0 buys) and a 20.4% 5-day drop creates high short-term execution uncertainty. This is algorithmic model output, not personal investment advice.
Is ARWR stock a buy?
The TradeMates model verdict for ARWR is WATCH (do not buy) with an investment score of 46/100. Treat this as a model signal to review, not a personal buy recommendation.